The application of these guidelines in clinical practices is very modest. Most of hypertensive patients are not assessed for risk stratification. Although JNC VI and even JNCVII, which will be released in the next months, continue to be recommended, a diuretic or beta-blocker should be used as first-line therapy unless there are compelling or specific indications for another drug. However, the proportion of these classes of drug has been used very limit. Have the pressing of commercial pharmacologic companies been affecting in a part?